2012
559 Predictive Markers of Gemcitabine Treatment Response in Pancreas Cancer: A Pharmacogenomic Pathway Approach
Farrell J, Moughan J, Wong J, Regine W, Scaefer P, Benson A, Macdonald J, Liu X, Yen Y, Lai R, Zheng Z, Bepler G, Guha C, Elsaleh H. 559 Predictive Markers of Gemcitabine Treatment Response in Pancreas Cancer: A Pharmacogenomic Pathway Approach. Gastroenterology 2012, 142: s-113. DOI: 10.1016/s0016-5085(12)60424-7.Peer-Reviewed Original Research
2011
Su1384 Development and Validation of an EUS-FNA-Based Predictive Marker of Gemcitabine Response in Pancreatic Cancer
Farrell J, Wong J, Donahue T, Rao J. Su1384 Development and Validation of an EUS-FNA-Based Predictive Marker of Gemcitabine Response in Pancreatic Cancer. Gastrointestinal Endoscopy 2011, 73: ab249-ab250. DOI: 10.1016/j.gie.2011.03.437.Peer-Reviewed Original Research
2009
163 Ribonulceotide Reductase M2 (RRM2): Predictive Marker of Response to Gemcitabine in Pancreatic Cancer
Farrell J, Garcia M, Liu X, Ammar A, Regine W, Abrams R, Elsaleh H. 163 Ribonulceotide Reductase M2 (RRM2): Predictive Marker of Response to Gemcitabine in Pancreatic Cancer. Gastroenterology 2009, 136: a-32. DOI: 10.1016/s0016-5085(09)60146-3.Peer-Reviewed Original Research